Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

J and J

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

- PMLiVE

J&J gets EU approval for depression nasal spray Spravato

Approved with a risk management plan to guard dosing

- PMLiVE

J&J’s Spravato breaks depression drought at FDA

The esketamine nasal spray is the first new-mechanism antidepressant to be licensed in decades

- PMLiVE

FDA panel backs J&J’s new-class antidepressant

Set to be first novel antidepressant approved since Prozac in 1987

- PMLiVE

J&J’s Erleada cleared for early prostate cancer in Europe

Signals competiton for Xtandi

- PMLiVE

Lundbeck challenge to EC pay-for-delay ruling fails

Court upholds €94m fine for paying off firms to delay launch of Celexa generics

- PMLiVE

Surging sales of Lundbeck’s CNS drugs assist recovery

Two newer antidepressants help boost sales after Cipralex patent ends

- PMLiVE

GSK accused of delaying generic Seroxat in UK

Could be fined 10 per cent of global turnover if found to have infringed competition law

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links